GlassScriptPhysician profile
Deborah Kerrigan
NPI 1750700647
$6,913.03
in general payments reported to CMS, 2019-2025
32 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 77% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $369 · 2021: $606 · 2022: $951 · 2023: $1,784 · 2024: $1,072 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,063.84 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $614.94 | 2021-2025 | Farxiga, Brilinta |
| Agepha Pharma Fz LLC | $502.80 | 2025 | Lodoco |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $502.62 | 2020-2024 | Lifevest |
| Inari Medical, INC. | $461.21 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $378.56 | 2024-2025 | |
| Medtronic, INC. | $232.01 | 2021-2023 | |
| Penumbra, INC. | $224.82 | 2023 | Indigo System, Real Immersive System |
| Biotronik INC. | $206.61 | 2024-2025 | Recross, Orsiro Mission |
| Novartis Pharmaceuticals Corporation | $203.01 | 2023-2025 | |
| Teleflex LLC | $200.64 | 2023 | Turnpike, Guideliner, Supercross |
| Boston Scientific Corporation | $196.04 | 2019-2022 | |
| Heartflow, INC. | $188.94 | 2024-2025 | |
| Philips North America LLC | $183.38 | 2023-2024 | (Br3) Coronary Other |
| Recor Medical INC | $180.84 | 2024 | Paradise Renal Denervation System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $149.36 | 2025 | |
| Abbott Laboratories | $148.57 | 2022 | |
| Verge Medical, INC. | $147.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $136.34 | 2022 | |
| Siemens Medical Solutions USA, INC. | $132.37 | 2022 | |
| Opsens INC. | $113.38 | 2019 | |
| Celonova Biosciences, INC. | $108.03 | 2019 | |
| Corcym INC | $106.65 | 2023-2025 | Carbomedics Supra-Annular (Top Hat), Perceval |
| Chiesi USA, INC. | $97.07 | 2022 | |
| Novo Nordisk INC | $93.07 | 2023 | |
| Esaote North America, INC. | $89.73 | 2020 | |
| Cordis US Corp. | $81.87 | 2025 | Mynx Control Venous |
| Regeneron Pharmaceuticals, INC. | $68.52 | 2019 | |
| Livanova USA, INC. | $42.91 | 2023 | Tandemheart |
| Cardiovascular Systems INC. | $37.66 | 2020 | |
| Janssen Scientific Affairs, LLC | $19.48 | 2023 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.